{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:16:27Z","timestamp":1785287787396,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.abd.2024.08.008","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:25:49Z","timestamp":1743391549000},"page":"429-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-7080","authenticated-orcid":false,"given":"J\u00falia Opolski Nunes","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-6511","authenticated-orcid":false,"given":"Rodrigo Ribeiro","family":"e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6323-2234","authenticated-orcid":false,"given":"Paulo Victor","family":"Zattar Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4989-9909","authenticated-orcid":false,"given":"Patr\u00edcia Silva","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6550-3715","authenticated-orcid":false,"given":"Raquel Bissacotti","family":"Steglich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2024.08.008_bib0005","article-title":"Efficacy and safety of Dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.abd.2024.08.008_bib0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol."},{"key":"10.1016\/j.abd.2024.08.008_bib0015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/ijd.16678","article-title":"Efficacy and safety of biological agents for pemphigoid: a systematic review and meta\u2010analysis","volume":"62","author":"Lin","year":"2023","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0020","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40257-020-00513-3","article-title":"A review comparing international guidelines for the management of bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, and epidermolysis bullosa acquisita","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2024.08.008_bib0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0001-7310(08)74715-X","article-title":"Practical management of the most common autoimmune bullous diseases","volume":"99","author":"Su\u00e1rez-Fern\u00e1ndez","year":"2008","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.abd.2024.08.008_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hyb.2011.0102","article-title":"Functional characterization of an IgE-Class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180","volume":"31","author":"Messingham","year":"2012","journal-title":"Hybridoma (Larchmt)."},{"key":"10.1016\/j.abd.2024.08.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low\u2010dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatologic Therapy."},{"key":"10.1016\/j.abd.2024.08.008_bib0040","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs."},{"key":"10.1016\/j.abd.2024.08.008_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111157","article-title":"Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study","volume":"125","author":"Huang","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.abd.2024.08.008_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110050","article-title":"The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China","volume":"118","author":"Qi","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.abd.2024.08.008_bib0055","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.abd.2024.08.008_bib0060","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"key":"10.1016\/j.abd.2024.08.008_bib0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Syst Rev"},{"key":"10.1016\/j.abd.2024.08.008_bib0070","unstructured":"cochrane.org [Internet]. GRADE Handbook n.d. [cited 2024 Jan 4]. Avaiable from: https:\/\/training.cochrane.org\/resource\/grade-handbook"},{"key":"10.1016\/j.abd.2024.08.008_bib0075","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.abd.2024.08.008_bib0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/bjd\/ljad136","article-title":"Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients","volume":"189","author":"Moghadam","year":"2023","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0085","first-page":"480","article-title":"Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study","author":"Liuqi","year":"2022","journal-title":"Chin J Dermatol"},{"key":"10.1016\/j.abd.2024.08.008_bib0090","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0095","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jaad.2023.03.036","article-title":"Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: a multicenter retrospective review","volume":"89","author":"Learned","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0105","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1111\/jdv.17999","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real\u2010life study","volume":"36","author":"Velin","year":"2022","journal-title":"Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.08.008_bib0110","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1002\/iid3.924","article-title":"Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: a preliminary study","volume":"11","author":"Hu","year":"2023","journal-title":"Immun Inflamm Dis."},{"key":"10.1016\/j.abd.2024.08.008_bib0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2024.08.008_bib0125","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0130","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0135","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/jdv.16363","article-title":"Anti\u2010BP180 autoantibody levels at diagnosis correlate with 1\u2010year mortality rates in patients with bullous pemphigoid","volume":"34","author":"Monshi","year":"2020","journal-title":"Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2024.08.008_bib0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.abd.2024.08.008_bib0145","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.det.2011.06.003","article-title":"Evidence-based management of bullous pemphigoid","volume":"29","author":"Daniel","year":"2011","journal-title":"Dermatol Clin."},{"key":"10.1016\/j.abd.2024.08.008_bib0155","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2024.08.008_bib0160","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0165","article-title":"Interventions for bullous pemphigoid","volume":"8","author":"Singh","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.abd.2024.08.008_bib0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0180","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: A review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.08.008_bib0185","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archdermatol.2009.53","article-title":"Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study","volume":"145","author":"Bernard","year":"2009","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.abd.2024.08.008_bib0190","unstructured":"Regeneron Pharmaceuticals. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid. clinicaltrials.gov; 2023."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T14:38:22Z","timestamp":1751553502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059625000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0365059625000248"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2024.08.008","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}